Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1642 1645 1646 1651 1671
This examiner grants 51% of resolved cases
Laura B Goddard is an examiner in Tech Center 1600, Art Unit 1618, with 1282 resolved cases. The examiner has an allowance rate of 50.9 percent, which is a moderate rate, showing that about half of the 1282 resolved cases are eventually granted. The data provides a robust statistical foundation for understanding the examiner's disposition in Art Unit 1618.
The interview lift is 13.5 percent, which is a positive increase. This indicates that conducting an interview is associated with a higher likelihood of allowance than the 50.9 percent baseline. Practitioners should consider an interview to help move their applications toward a grant, as the 13.5 percent lift shows it is an effective way to resolve issues. This metric supports direct engagement.
The median days to allowance for this examiner is 1181. This timeline provides a benchmark for the expected duration of the prosecution process in Tech Center 1600. With the allowance rate and the 1181 day median, practitioners can set realistic expectations for their clients. The 1181 day duration is a key factor for planning in Art Unit 1618.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19454185 | haNK Cetuximab Combinations And Methods | Final Rejection | NantCell, Inc. |
| 17877195 | COMBINATION THERAPY WITH NEOANTIGEN VACCINE | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | Final Rejection | Genentech, Inc. |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | Non-Final OA | GENENTECH, INC. |
| 18553042 | VACCINE COMPOSITION AGAINST CORONAVIRUS | Final Rejection | LG CHEM, LTD. |
| 18409276 | METHODS AND COMPOSITIONS FOR ACTIVATION OF T CELLS USING NANOPARTICLES CONJUGATED WITH MULTIPLE LIGANDS FOR BINDING RECEPTORS ON T CELLS | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18035160 | HLA CLASS II-RESTRICTED TCRS AGAINST THE KRAS G12>V ACTIVATING MUTATION | Non-Final OA | The Regents of the University of California |
| 18478808 | CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18059719 | Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic Agent | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18438746 | METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR | Non-Final OA | Sanofi Biotechnology |
| 17786917 | METHODS FOR TREATING GLIOBLASTOMA | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17193511 | TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18561044 | POLY-ADP RIBOSE (PAR) TRACKER OPTIMIZED SPLIT-PROTEIN REASSEMBLY PAR DETECTION REAGENTS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18022593 | Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same | Final Rejection | The University Of Tokyo |
| 17535492 | METHODS OF TREATING UROTHELIAL CARCINOMA | Final Rejection | Foundation Medicine, Inc. |
| 18052840 | COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 | Final Rejection | AstraZeneca UK Limited |
| 18038159 | BISPECIFIC ANTIBODY AND USE THEREOF | Final Rejection | KEYMED BIOSCIENCES CO.,LTD |
| 18389951 | ANTI-PD-1×4-1BB BINDING PROTEINS | Non-Final OA | Genzyme Corporation |
| 17667714 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS | Final Rejection | Meso Scale Technologies, LLC. |
| 17394512 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS | Non-Final OA | Meso Scale Technologies, LLC. |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | Final Rejection | Merus N.V. |
| 17283939 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | Non-Final OA | Genome Research Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy